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The right ventricular outflow tract (RVOT) has a distinct embryological
origin and is a common anatomical source of arrhythmias in the healthy and dis-
eased myocardium. We hypothesised that specific RVOT activation and conduc-
tion properties may underlie the preferential RVOT origin of arrhythmias. Pig
right ventricular (RV) wedge preparations were perfused via the left anterior
descending and right coronary arteries. Electrical activation and conduction
properties were obtained by optical mapping of the epicardial surface (di-4-
ANEPPS 10μM) upon electrical stimulation of the preparation. Transmural nee-
dles were inserted in the RV free wall and RVOT and unipolar electrograms
(EGMs) were recorded. Fiber orientation was obtained by diffusion tensor MRI.
Regional mRNA expression was determined by RT-PCR and fibrosis was
assessed histologically. Longitudinal and transverse conduction velocities were
significantly reduced in RVOT compared to RV free wall (P<0.01). A different
direction of propagation was observed in the RVOT compared to the RV free
wall and a line of slowed propagation was found at the interface between the
2 regions. This was consistent with a 135±2° change in fiber orientation
observed between the 2 regions within a restricted distance (<6cm). The RVOT
showed more sites with fractionated EGMs (P<0.01) and more deflections per
electrode (P<0.001) than the RV free wall. In line with these findings, a
decreased expression of Scna5 and Gja1 was found in the RVOT compared to
the RV free wall (P<0.001). Moreover, the RVOT was characterized by an
upregulation of type I collagen mRNA, a higher collagen content (P<0.05) and
the presence of fat infiltrations which were absent in the free wall.
Conduction is slower in the pig RVOT and is associated with fractionated
unipolar electrograms. Conduction slowing was related to (i) reduced con-
nexin and sodium channel expression and (ii) region-specific structural prop-
erties which may generate a substrate for RVOT arrhythmias.
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Background: Extracorporeal life support (ECLS) provides mechanical car-
diopulmonary support and has been used for intractable heart failure as a
bridge to heart transplantation or to recovery. Intractable arrhythmic storm is
associated with high mortality. Little is known about the effectiveness of
ECLS to treat refractory ventricular arrhythmias responsible for cardiogenic
shock in patients non eligible for an urgent ablation.
Methods: Patients with intractable refractory ventricular arrhythmias and
cardiogenic shock despite optimal medical therapy, and treated by ECLS
implantation were retrospectively included. Patients’ characteristics and out-
come were analyzed.
Results: 20 patients (53±10 yo) were included. The underlying etiology to
the refractory ventricular storm was ischemic cardiomyopathy (75%), short
coupled Torsades de Pointes (10%), dilated cardiomyopathy (5%), myocarditis
(5%) or unknown (5%). Mean LVEF was 33±17%. An average of 2.3±1.2
anti-arrhythmic drugs was tried before implantation. Arrhythmic storm
stopped after a median time of 15min after ECLS implantation. 8 patients
(40%) eventually died, none of them because of a complication of ECLS
implantation. The remaining 12 patients (60%) had ECLS withdrawn after a
median time of 5.3 days, and were discharged after a median time of 29 days
after admission (survival curve in the figure).
Conclusion: This is the largest database of patients temporary
implanted with ECLS for refractory ventricular arrhythmia responsible for
cardiogenic shock and non eligible for ablation. It provides efficient hemo-
dynamic support to these critically ill patients, and survival rate after the
implantation is 60%.
Abstract 0230-Figure: Survival curve
0334
Implantable cardioverter defibrillator in primary prevention for
chronic heart failure: incidence and predictors of appropriate therapy
Arsène Monnier (1), François Lesaffre (1), Pierre Nazeyrollas (1), Aurélie
Marchais (2)
(1) CHU Reims, Hôpital Robert Debré, Cardiologie, Reims, France – (2)
CH Troyes, Cardiologie, Troyes, France
Background: Considering morbidity and financial impact on the health care
system, it may be helpful to stratify patients who would most benefit from primary
ICD treatment. The aim of this study was to assess the prevalence and identify the
clinical predictors of appropriate ICD therapy in patients following implantation of
an ICD in primary prevention for chronic heart failure.
Methods: A monocenter retrospective analysis was performed and all
patients undergoing implantation of ICD in primary prevention were included.
Device interrogations were performed and appropriate therapies, either ATP
or shock, were noticed.
Results: Over the 317 primary prevention patients undergoing ICD
implantation, 203 had ischemic cardiomyopathy (ICM) and 114 had non-
ischemic dilated cardiomyopathy (NIDCM). At the median follow-up time
760±599 days, 56 (17,7%) had received appropriate ICD therapies. Average
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